• If this is your first visit, be sure to check out the FAQ & read the forum rules. To view all forums, post or create a new thread, you must be an AAPC Member. If you are a member and have already registered for member area and forum access, you can log in by clicking here. If you've forgotten the password it can be reset on our sign in section by entering your registered Email Address or Username here. To start viewing messages, select the forum that you want to visit from the selection below..

Wiki Pathology Immunohistochemistry PD-L1 (immunohistochemistry clone 22C3)

Create Wiki
W

WilliamLowder

Guest
Messages
1
Best answers
0
The PD-L1 companion diagnostic test for Keytruda (immunohistochemistry clone 22C3) is interpreted using a Tumor Proportion Score (TPS); however, the result that is rendered is qualitative and the package insert from Dako indicates that this is a “qualitative” test. With this logic, our institution has been using CPT 88342, but we’re wondering what others are doing, as 88360 certainly feels more accurate for the work that goes into this interpretation as well as the fact that we are also reporting the TPS on the reports. Our quandary also lies in the fact that if we change the code to 88360, we would need to update our interpretive data which would stray from the vendor’s package insert. Is anyone else doing this? Any guidance or input is welcome.
 
You must log in or register to reply here.
Top